Cancertrack - Non-Invasive Liquid Biopsy
CancertrackTM is a non-invasive blood based investigation that detects cancer derived biomarkers with ultra-high precision, specificity and reliability. CancertrackTM can be used to monitor the disease /recurrence or changes in the tumor characteristics, as often as necessary, without the cost, risk and consequences of radiation from scans, hospitalisation, anaesthesia or painful surgical biopsies.
- Indication of cancerous activity in the body.
- Indication of molecular dynamics in real-time.
- Indication of therapy success.
- Molecular sign of drug resistance.
- Indication of targetable molecular alteration.
- Every person who has been diagnosed with cancer, as a supplement to conventional biopsy for a more robust molecular diagnosis and baseline measurement of cell-free tumor DNA before initiation of therapy.
- Every patient who is under treatment for cancer.
- Every patient who is in remission / a cancer survivor and needs monitoring.
- Every patient in whom the cancer is not responding satisfactorily to “Standard of Care” therapy.
Radiological imaging is not always able to detect changes in the tumor at the molecular level or early signs of recurrence. Additionally, there are inherent risks associated with radiological imaging.
cfDNA from the patient’s peripheral blood is analysed for qualitative and quantitative changes in targeted genes.
15 / 20 ml peripheral blood (5-6 hours fasting) as per protocol.
Report will be available within 10-12 days.
- Multi-coordinate and multidimensional probes to track down DNA released by cancer cells in the patient’s blood.
- Unique, unprecedented capability to detect cancerous activity.
- Enables real-time rapid response to the dynamic molecular profile of a patient’s cancer.
- Safe, sure, simple and cost-effective.
- Non-invasive blood test.
- Not dependent on availability of tissue.
- Tests all active disease sites.
- Limit of detection is 0.1% Mutant Allele Frequency.
- Far more powerful than conventional biopsy.
- Extensive coverage of NCCN recommended biomarkers.